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Abstract
Background: To determine differentially expressed and spliced RNA transcripts in chronic lymphocytic leukemia
specimens a high throughput RNA-sequencing (HTS RNA-seq) analysis was performed.
Methods: Ten CLL specimens and five normal peripheral blood CD19+ B cells were analyzed by HTS RNA-seq. The
library preparation was performed with Illumina TrueSeq RNA kit and analyzed by Illumina HiSeq 2000 sequencing
system.
Results: An average of 48.5 million reads for B cells, and 50.6 million reads for CLL specimens were obtained with
10396 and 10448 assembled transcripts for normal B cells and primary CLL specimens respectively. With the Cuffdiff
analysis, 2091 differentially expressed genes (DEG) between B cells and CLL specimens based on FPKM (fragments
per kilobase of transcript per million reads and false discovery rate, FDR q < 0.05, fold change >2) were identified.
Expression of selected DEGs (n = 32) with up regulated and down regulated expression in CLL from RNA-seq data
were also analyzed by qRT-PCR in a test cohort of CLL specimens. Even though there was a variation in fold
expression of DEG genes between RNA-seq and qRT-PCR; more than 90 % of analyzed genes were validated by
qRT-PCR analysis. Analysis of RNA-seq data for splicing alterations in CLL and B cells was performed by Multivariate
Analysis of Transcript Splicing (MATS analysis). Skipped exon was the most frequent splicing alteration in CLL
specimens with 128 significant events (P-value <0.05, minimum inclusion level difference >0.1).
Conclusion: The RNA-seq analysis of CLL specimens identifies novel DEG and alternatively spliced genes that are
potential prognostic markers and therapeutic targets. High level of validation by qRT-PCR for a number of DEG
genes supports the accuracy of this analysis. Global comparison of transcriptomes of B cells, IGVH non-mutated CLL
(U-CLL) and mutated CLL specimens (M-CLL) with multidimensional scaling analysis was able to segregate CLL and
B cell transcriptomes but the M-CLL and U-CLL transcriptomes were indistinguishable. The analysis of HTS RNA-seq
data to identify alternative splicing events and other genetic abnormalities specific to CLL is an added advantage of
RNA-seq that is not feasible with other genome wide analysis.
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Background
Chronic lymphocytic leukemia (CLL) is a common
leukemia characterized by accumulation of B cells in the
blood, marrow and lymphatic tissues. The clinical course
is highly variable with biological and genetic heterogen-
eity in leukemic specimens. A number of genetic alter-
ations have been correlated with prognosis [1–5];
however, the ability to prognosticate outcomes and tailor
treatment based on genetic alterations is still limited. To
identify genetic alterations in CLL, a number of different
methods have been employed including cytogenetic stud-
ies [6], and array comparative genomic hybridization
CGH [7, 8] and recently whole exome sequencing [9]. The
whole exome sequencing of CLL specimens has also re-
sulted in the identification of novel recurring mutations in
theMYD88, NOTCH1, KLH6 and SF3B1 genes [10].
To study the complete transcriptome of cells, microar-
rays have been extensively used, and these studies have
identified a number of differentially expressed genes
[11–14]. Microarray techniques are, however, subject to
a number of limitations including, cross hybridization of
transcripts, limitation in coverage, inability to resolve
novel transcripts and a falsely higher estimation of low
abundance transcripts [15–18]. With the development of
massive parallel RNA sequencing (RNA-seq) technology,
there have been a growing number of genome-wide stud-
ies that have analyzed the complete transcriptome cells in
different malignancies [18–22] and non-malignant dis-
eases [23, 24]. Besides analyzing the expression level of
genes the RNA-seq technology has the added advantage
of analyzing expression at the exon level and provides de-
tailed information about alternative splicing variations,
novel transcripts, fusion genes, differential transcription
start sites and genomic mutations [25, 26]. As all the RNA
transcripts are being directly sequenced, this technology is
ideally suited to study altered splicing pattern which is
especially relevant in cancer cells as they are known to
express unique RNA isoforms with varied biological ef-
fects [27, 28].
In this study, we performed RNA-seq analysis on CLL
specimens and normal peripheral blood B cells to deter-
mine transcriptome differences and splicing variations.
The data obtained from the RNA-seq analysis was vali-
dated by real time PCR on the RNA-seq cohort and a
test cohort of specimens. Besides expression analysis a
number of novel differentially spliced genes were also
identified and analyzed. These findings will facilitate the
identification of novel prognostic markers, therapeutic
targets and signaling pathways in CLL.
Methods
Sample isolation and characterization
Primary CLL specimens analyzed in this study were ob-
tained from untreated CLL patients after appropriate
human subject approval. The human subject study was
approved by the ethics committee of the West Los
Angeles VA Medical Center and an informed written
consent was obtained from all patients. A peripheral
blood draw was performed, and peripheral blood lym-
phocytes (PBLs) were isolated by ficoll gradient. In all
the CLL specimens, more than 90 % of isolated cells
were CD19+ by flow cytometry analysis. Total RNA
from isolated B cells (five different normal donors, cau-
casian males) was purchased from ALLCELLS (Alameda,
CA). IGVH mutation (Immunoglobulin variable region
heavy chain) analysis was performed on the CLL speci-
mens with multiplexed PCR reactions to assess clonality
as previously described [29]. Percentage of CLL cells ex-
pressing CD38 marker and Zap-70 (intracellular stain-
ing) was determined by flow cytometry and specimens
with more than 20 % cells expressing Zap-70 were de-
fined as Zap-70 positive. CLL specimens in a separate
test cohort (n = 47) were from all clinical stages, chemo-
therapy naïve, and with more than 90 % CD19+ cells.
RNA-seq and library preparation
For library preparation, the Illumina TruSeq RNA sam-
ple Prep Kit v2 (San Diego, CA) was used according to
the manufacturer’s protocol. Briefly, 1 μg of total
mRNAs from five normal B and ten CLL cells was poly-
A purified, fragmented, and first-strand cDNA reverse
transcribed using random primers. Following second-
strand cDNA synthesis, end repair, addition of a single
A base, adaptor ligation, and PCR amplification, the
enriched cDNA libraries were sequenced using the Illu-
mina HiSeq 2000 at the UCLA Broad Stem Cell Re-
search Center High Throughput Sequencing Core. The
RNA sequencing data is deposited at GEO website, ac-
cession number GSE70830.
Primary processing and mapping of RNA-seq reads
50 bp single-end RNA-seq reads were obtained from
Illumina HiSeq 2000. Sequence files were generated in
FASTQ format (sequence read plus quality information
in Phred format). RNA-seq data were analyzed using the
UCLA Galaxy server (galaxy.hoffman2.idre.ucla.edu).
The quality score of RNA-seq reads was obtained by
using the FastQC and the mean quality of each base pair
in the samples was 28, indicating a good-quality call in
the 50 bp reads [30]. Reads were then processed and
aligned to the UCSC H. sapiens reference genome (build
hg19) using TopHat v1.3.3 [31–33].
Assembly of transcripts and differential expression
The aligned read BAM files were assembled into tran-
scripts, their abundance estimated and tests for differen-
tial expression processed by Cufflinks v2.0.1 [33].
Cufflinks uses the normalized RNA-seq fragment counts
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to measure the relative abundances of transcripts. The
unit of measurement is fragments per Kilobase of exon
per Million fragments mapped (FPKM). Confidence in-
tervals for FPKM estimates were calculated using a
Bayesian inference method. After assembly with Cuf-
flinks, the output files were sent to Cuffmerge along
with a reference annotation file. To normalize multiple
samples for differential expression analysis, we utilized a
“geometric” method as described in Anders and Huber
[34]. For cross-replicate dispersion estimation, a “pooled”
method was used in which each replicated condition is
used to build a model, and then these models are averaged
to provide a single global model for all conditions in the
experiment. The expression testing was done at the level
of transcripts and genes and pairwise comparisons of ex-
pression between normal and CLL samples. Only the
comparisons with “q-value” less than 0.05 and expression
fold change greater than two fold in the Cuffdiff output
were regarded as showing significant differential expres-
sion. Downstream analysis for Cuffdiff output was done
using CummeRbund [34].
RT-PCR validation of RNA-seq results
The differentially expressed genes were validated by
Quantitative Real-time Polymerase Chain Reaction
(qRT-PCR) using a StepOnePlus™ Real-Time PCR Sys-
tem (Life technologies). cDNA templates from five nor-
mal B cell and ten CLL cells were analyzed for
expression of DSP, TRIB2, DUSP1, FOS, JUN, SELPLG,
AMICA, MMP9, TYROBP, and LEF1 with taqman
probes obtained from Applied Biosystems. The probes
selected for these genes provide the best coverage so
that the majority of transcripts of the gene are quantified
(further information is available on request). To analyze
the IGVH subgroups, expression of three genes T, TFEC
and IGLL5 was also determined with Taqman probes.
Expression of a number of reference genes (Actin, Riboso-
mal protein large PO, phosphoglycerate kinase, Hypoxan-
thine phoshoribosyl transferase and Transferrin receptor)
was tested for expression in CLL and B cells, and actin
was selected as the standard reference gene and the data
was analyzed by the method of Pfaffll [35].
Functional annotation of differentially expressed genes
The differentially expressed gene lists were submitted to
Ingenuity Pathway Analysis (IPA, Ingenuity Systems).
The functional annotation identifies the biological func-
tions that are most significant to the data set. A Fisher’s
exact test was used to calculate a p-value determining
the probability that the association between the genes in
the dataset and the functional annotation is explained by
chance alone.
Alternative splicing analysis with MATS
The RNA-Seq data of B cells and CLL specimens was
analyzed for splicing alterations. To identify such events,
MATS 3.0.8 (Multivariate Analysis of Transcript Spli-
cing, ref [36]) was used to determine junctional reads
within ENSEMBL human gene annotations. This soft-
ware implements a Bayesian approach that detects dif-
ferential AS (alternative splicing) under two conditions
by examining whether the difference in the exon-
inclusion levels between two samples exceeds a given
user-defined threshold. To identify these events, we used
the following criteria, 1. Splicing events were labeled sig-
nificant if the sum of the reads supporting a specific
event exceeded 10 reads, 2. P-value was <0.05, and 3.
Minimum inclusion level difference as determined by
MATS was >0.1 (10 % difference). To validate the spli-
cing alterations RT-PCR analysis was performed by de-
signing primers in the neighboring exons (primer
sequences available on request).
Results
Analysis of RNA-seq data
Five normal CD19+ B Cell RNA from different donors
(B1 to B5), six IGVH un-mutated primary CLL specimens
(CLL6, CLL9, CLL25, CLL28, CLL40, and CLL44) and
four IGVH mutated CLL specimens (CLL26, CLL32,
CLL37, and CLL39) were subjected to HTS-RNA single-
end RNA sequencing (Table 1). The total WBC counts for
unmutated IGVH (U-CLL) were higher than mutated
IGVH (M-CLL) specimens (Table 1) and the U-CLL spec-
imens were noted to have a higher percentage of leukemic
cells expressing CD38 and Zap-70 as described before [4,
5]. The total number of raw reads in B cells (n = 5) and
CLL (n = 10) specimens ranged from 31 to 85 million
reads, and 37 to 101 million for normal, CLL, respectively
(Fig. 1, Additional file 1). To assess the quality of mapping
reads to the reference genome hg19, some key metrics
were extracted from the TopHat output, and analyzed
using the RNA-seq quality control package RseQC [37].
The majority of reads (between 65.5 % and 79.6 %) are
uniquely mapped to the reference genome sequences
across all samples (Additional file 1). The mean mapping
percentage for normal B cells and CLL specimens is
78.3 % and 74.4 % and 5.8 % to 8.8 % of the reads mapped
to the known splice junctions respectively.
To further examine the read distribution, the uniquely
mapped reads were assigned to: exon coding sequence
(CDS_Exons), 5’ and 3’ untranslated regions (UTR_Ex-
ons), introns and intergenic regions. In Fig. 1a, the dis-
tribution of mapped reads is shown across the samples.
41 % to 52 % of reads mapped to exon coding sequence,
2.9 % to 3.8 % mapped to 5’UTR while 18 % to 25 %
mapped to 3’UTR. The introns and intergenic regions
account for about 15–30 % and 5–9 %, respectively (data
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for all specimens is in Additional file 1). To compare if
there is a difference in read distribution between normal
B cell and CLL, mapping data from Fig. 1a was averaged
and plotted as a pie chart in Fig. 1b. The exonic reads
(CDS_Exons) were higher in CLL specimens as compared
to B cells while intronic reads were higher in the B cell
specimens (Fig. 1b), 30 % vs. 16 % for normal B cells and
CLL specimens. The high number of reads mapping to in-
trons have been reported in other RNA-seq analysis [38]
and could be due to genomic DNA contamination,
A
B
Fig. 1 Distribution of sequencing reads in normal B cells and CLL specimens. a The bar diagram represents distribution of uniquely mapped reads to
human genome UCSC_hg19 (GRCh37). Each bar depicts the percentage of reads from individual samples (five normal B cell and ten CLL specimens)
mapped to coding sequence exon (CDS_exon), 5’ and 3’ untranslated regions (5’ and 3’UTR_Exons), introns and intergenic regions. b Pie charts represent
the average percentage of sequencing reads from five normal B cell (left) and ten CLL specimens (right) that map to the above mentioned regions
Table 1 Clinical characteristics of CLL patients and RNA sequencing read count data
Age sex, Rai stage, total WBC count (cumm3) % cells CD38+ Zap-70 status Specimen
Normal CD19+ B cells B1
B2
B3
B4
B5
U-CLL 67 M, stage II, 40,000 0 % neg CLL6
88 M, stage III, 90,000 59 % pos CLL9
62 M, stage I, 96,000 24 % pos CLL25
71 M, stage II, 135,000 8 % pos CLL28
56 M, stage II, 102,000 55 % pos CLL40
68 M, stage IV, 320,000 50 % pos CLL44
M-CLL 55 M, stage III, 37,000 0 % ND CLL26
61 M, stage 0, 24,000 5 % neg CLL32
64 M, stage I, 28,000 0 % pos CLL37
78 M, stage III, 98,000 0 % neg CLL39
(neg, negative, pos, positive, ND, not done, M-CLL mutated IGVH, U-CLL non-mutated IGVH)
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sequencing of pre-mRNA, novel exons, or nascent tran-
scription and co-transcriptional splicing as described in
Ameur et al [39].
Defining the transcriptomic profiles of normal B cell, and
CLL specimens
To examine the transcriptome profile of normal B cells
and primary CLL specimens, transcripts were assembled
and their expression values calculated using Cufflinks.
Pair-wise comparisons of transcriptomic profiles of normal
B cells, CLL specimens as well as disease-subtype as deter-
mined by IGVH mutational status (U-CLL, un-mutated
IGVH and M-CLL, mutated IGVH), were performed. The
transcript abundance was calculated by estimating the
fragment per kilobase of exon per million mapped frag-
ments (FPKM). The numbers of assembled transcripts for
normal B cell, U-CLL and M-CLL were 10396, 10494, and
10402 and the genes identified for the three sample groups
were 10081, 10111, and 10068, respectively (Additional file
2A). Overall, the number of transcripts and genes found in
three groups are very similar indicating a uniform sequen-
cing depth in the various groups.
To determine significant differences in the transcrip-
tomic profiles in the three sample groups (B, U-CLL and
M-CLL), pair wise scatter plots matrix was generated by
CummeRbund [34]. This analysis compares and corre-
lates the FPKM profile of all expressed genes in all three
sample groups, and it also shows the density distribution
of FPKM for genes expressed. In Additional file 2B, the
density plot reveals that the FPKM distributions among
three sample groups are similar, and the FPKM of all
expressed genes ranged from 0.003 to 3000 (log10FPKM
-2.5 to 3.5), with the majority of the genes expressing
FPKM range from 1 to 100 (log10FPKM 0 to 2.5). The
global profiles of U- and M-CLL show fewer dispersion
as compared to plots where normal B cell data is com-
pared to the CLL specimens indicating similar transcrip-
tome profiles of U- and M-CLL specimens.
Analysis of differentially expressed genes
To determine the differentially expressed genes (DEG) be-
tween normal B cells and CLL specimens a Cuffdiff ana-
lysis was performed. After filtering differential expressed
genes with FDR-adjusted (FDR false discovery rate) q
value < 0.05 and fold change > 2, there were 2091 DEG
genes between CLL specimens and normal B cells (Fig. 2a).
Among these genes, 1231 were up-regulated in CLL and
860 genes were down-regulated (complete gene list in
Additional file 3), and the top twenty genes in each group
are shown in Table 2. The data was also analyzed by segre-
gating CLL specimens based on their IGVH status and
comparing them with normal B cells separately. With this
analysis 2425 and 1960 DEG genes were identified in U-
and M-CLL specimens respectively. Among these genes,
1332 and 1132 were up-regulated and 1093 and 828 were
down-regulated in U-CLL and M-CLL (Fig. 2a). In order
to find out if there are overlapping genes that are differen-
tially expressed in both U-CLL and M-CLL samples, the
gene lists from normal B cells vs. CLLs, normal B cells vs.
U-CLL and normal B cells vs. M-CLL were compared to
generate a Venn diagram (Fig. 2b). A high number (1382
genes out of 2091) of differentially expressed genes be-
tween normal B cells and CLLs were common to the U-
CLL and M-CLL specimens, indicating that this subgroup
includes a common set of differentially expressed genes.
To validate the RNA-seq data, a number of differen-
tially expressed genes with potential biological relevance
to CLL were selected from this analysis, and their FPKM
data was compared to the expression level by real time
RT- PCR (qRT-PCR). In an initial experiment the ex-
pression level of a number of reference genes in normal
B cells and CLL specimens was determined to identify
the appropriate reference gene. Actin, Ribosomal protein
large PO, Phosphoglycerate kinase, Hypoxanthine phos-
horibosyl transferase and Transferrin receptor expression
was analyzed with Taqman probes and the expression of
actin was the most abundant in all the CLL (n = 3) and B
A B
Fig. 2 Transcriptomic expression profiles and validation. a The number of statistically significant differentially (Up and Down regulated) expressed
genes identified from Cuffdiff analysis in various groups relative to B cells are shown in a table format. The differentially expressed genes (DEG,
FDR-adjusted q-value < 0.05, Fold change > 2) in all CLL specimens (n = 10), U-CLL (n = 6) and M-CLL (n = 4) was compared to normal B cells.
b Venn diagram illustrates the overlapped DEG between the three groups in panel A
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cell specimens (n = 3) and was selected as the standard
reference gene. FOS (# 111), JUN (#152), DSP (desmo-
plakin #2), TRIB2 (Tribbles homolog 2, #66) and DUSP1
(dual specificity phosphatase 1 # 49) were selected from
the set of genes that have a lower expression in CLL speci-
mens than B cells (Table 2, Additional file 3, # represent
the position of the gene based on the FPKM data, lower
number corresponds to higher down regulation). AMICA1
(#48), MMP9 (#2), TYROBP (#49), SELPG (# 604), LEF1
(#64) were selected as candidate genes to compare the fold
over-expression by the two methodologies (# represents
fold over-expression relative to B cell based on FPKM data,
smaller number indicates higher fold overexpression).
The RNA from the identical 10 CLL specimens and
five normal B cells (control) was used to perform Taq-
man probe based qRT-PCR assays. Probes selected for
expression analysis provide the best coverage for a par-
ticular gene. Figure 3a, b shows three sets of data for
each gene expression (n = 10), expression based of
FPKM values in RNA-seq cohort (n = 10), qRT-PCR data
from the identical specimens (n = 10) as RNA-seq cohort
(relative to actin) and qRT-PCR data of a test cohort (n =
47, relative to actin) of CLL specimens. Figure 3a bar dia-
gram depicts average ΔΔcT values in the three cohorts
with the table below showing the p values of data in Fig. 3a.
For down regulated genes in CLL, only DSP and TRIB2
expression is significantly lower (p < 0.5) as compared to B
cells, while in the set of up-regulated genes, the expression
of SELPG, AMICA, TYROBP and LEF1 is significantly
higher (p < 0.5) in the test cohort. MMP9 expression
though significantly higher in the smaller RNA-seq cohort
is not significantly higher in the test cohort.
Table 2 Top twenty up (positive fold change) and down-regulated (negative fold change) genes in CLL versus Normal B cells
Up-regulated genes Down-regulated genes
Genes Description Fold change q-value Genes Description Fold change q-value
FSTL1 follistatin-like 1 1360 ± 4372 0.0090 SYN3 synapsin III −270 0.0039
MMP9 matrix metallopeptidase 9
(gelatinase B, 92 kDa)
1060 ± 1501 0.0323 DSP desmoplakin −179 0.0222
FMOD fibromodulin 789 ± 1041 0.0008 FBLN2 fibulin 2 −134 0.0074
CXCL5 chemokine (C-X-C motif)
ligand 5
593 ± 1008 0.0043 ENAM enamelin −117 0.0103
ADTRP androgen-dependent TFPI-
regulating protein
586 ± 485 0.0031 HDC histidine decarboxylase −103 0.0270
KSR2 kinase suppressor of ras 2 528 ± 750 0.0232 CD1A CD1a molecule −99 0.0311
THBS1 thrombospondin 1 506 ± 640 0.0008 MYO1B myosin IB −73 0.0112
TGFBR3 transforming growth factor,
beta receptor III
459 ± 205 0.0392 LOC100505738 uncharacterized LOC100505738
or MIR4458
−66 0.0008
CYP1B1 cytochrome P450, family 1,
subfamily B, polypeptide 1
423 ± 512 0.0191 SLC45A3 solute carrier family 45, member 3 −47 0.0008
IL8 interleukin 8 411 ± 462 0.0015 MMRN1 multimerin 1 −46 0.0090
CD300E CD300e molecule 401 ± 650 0.0251 PPFIBP1 PTPRF interacting protein,
binding protein 1 (liprin beta 1)
−45 0.0031
PRF1 perforin 1 (pore forming
protein)
388 ± 265 0.0106 ZNF618 zinc finger protein 618 −44 0.0015
GIMAP7 GTPase, IMAP family
member 7
324 ± 305 0.0323 UACA uveal autoantigen with coiled-coil
domains and ankyrin repeats
−44 0.0083
CTLA4 cytotoxic T-lymphocyte-
associated protein 4
276 ± 255 0.0025 AHNAK2 AHNAK nucleoprotein 2 −44 0.0008
CD8A CD8a molecule 274 ± 257 0.0173 GATA2 GATA binding protein 2 −39 0.0121
NRP1 neuropilin 1 263 ± 475 0.0488 PARM1 prostate androgen-regulated
mucin-like protein 1
−39 0.0008
SFTPB surfactant protein B 261 ± 477 0.0052 CR1 complement component (3b/4b)
receptor 1
−39 0.0008
TNFRSF1A tumor necrosis factor
receptor superfamily,
member 1A
240 ± 140 0.0052 CABYR calcium binding tyrosine-(Y)-
phosphorylation regulated
−39 0.0264
HBB hemoglobin, beta 234 ± 553 0.0020 LOC100506178 uncharacterized LOC100506178 −36 0.0209
CYBRD1 cytochrome b reductase 1 216 ± 254 0.0020 FFAR1 free fatty acid receptor 1 −34 0.0224
(q value: adjusted p-value)
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Figure 3b Table compares the fold expression ob-
tained by these analysis, as an example in the case of
DSP the difference in cT values between actin and DSP
RNA is around 10 cycles while the expression in CLL
cohorts is around 8 cycles lower, i.e. 256 fold fold
down regulation of DSP expression in CLL specimens
as compared to B cells. This lower DSP expression in
CLL specimens is similar to the results obtained from
FPKM analysis (179 fold lower expression in CLL).
FOS and JUN expression based on RNA-seq FPKM
data is 7.9 and 6.2 fold less than B cells while based on
the qRT-PCR analysis their expression is 4.6 and 4.2
fold less than B cells. However in the test cohort (n =
47) the lower expression of JUN cannot be confirmed
and for FOS the fold lower expression is less than the
RNA-seq data (1.7 vs 7.9). Similar variability in ex-
pression is observed for MMP9 and AMICA1 expres-
sion as the fold expression vary 20 to 35 fold when
analyzed by RNA-seq FPKM and qRT-PCR. The ana-
lysis shows that genes identified as differentially
expressed by RNA-seq can be confirmed by qRT-PCR
analysis, however the fold expression obtained by the
two analysis are variable. Also confirmation with
qRT-PCR in additional primary CLL specimens is re-
quired as there is significant variability of expression
in leukemic cells.
Based on this analysis, additional DEG genes were se-
lected to further compare the two methodologies for
RNA expression (Table 3). FPKM and qRT-PCR fold ex-
pression levels were compared in the RNA-seq cohort
and a test cohort of CLL specimens (n = 22). Nine down-
regulated genes from the RNA-seq data were randomly
selected and their expression compared to qRT-PCR
analysis. In the case of PTPRK, expression in normal B
cells was not identified by qRT-PCR and therefore the
RNA-seq data could not be validated. In the case of
CCD69, the expression by RNA-seq and qRT-PCR is
similar but this lower expression is not observed in our
test cohort. Besides these two examples, qRT-PCR con-
firms a lower expression of these genes in CLL speci-
mens as compared to normal B cells. Twelve genes with
a range of over-expression were randomly selected from
the list of over-expressed genes from the RNA-seq ana-
lysis (Additional file 3) and analyzed by qRT-PCR
(Table 3). All the genes were found to be over-expressed
based on qRT-PCR in the RNA-seq and test cohort how-
ever the expression was variable. Difference in fold
expression was observed when the identical specimen
was tested by both methodologies as well. Possible
explanations for this discrepancy are the normalization
of RNA-seq data and the use FPKM for calculation
while qRT-PCR analysis is relative expression to a
A
B
Fig. 3 Validation analysis of selected differentially expressed genes. a qRT-PCR of selected genes on B cells (n = 5), CLL specimens, RNA seq cohort
(n = 5) and CLL specimens, test cohort (n = 47). Data shown is the delta delta cT relative to actin. (Mean and standard deviation). Table below
panel A shows the P-values of the qRT-PCR data for the comparison of B cells and CLL RNA seq cohort (n = 10), and B cells and CLL test cohort.
(t-test). b Fold expression of selected genes in the larger CLL cohort (n = 47) based on qRT-PCR analysis. * PTPRK expression was not detected in
normal B cells therefore fold change could not be calculated
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housekeeping gene and the Taqman probe may not pro-
vide coverage for all the transcript variants.
Functional pathway analysis
The functional analysis tool was used to categorize genes
that were differentially expressed in CLL specimens.
Genes from Additional file 3 were analyzed by IPA ana-
lysis. The output of the functional annotation is shown
in Additional file 4 and the list of genes in each pathway
are in Additional file 5. The highest number of DEG
genes are in the cell death and survival group correlating
well with the unique biological characteristic of CLL,
namely resistance to apoptosis. Other significant cluster-
ing of genes is observed in cellular movement, cellular
development, cellular growth and proliferation and can-
cer pathways.
Comparison the CLL IGVH mutated and non-mutated
transcriptomes
Based on the Cuffdiff analysis in Fig. 2a and b a number
of genes are differentially expressed in the two CLL sub-
sets, M and U-CLL. A total of 679 genes were more than
2 fold up or down regulated when the average FPKM
data of all the genes was compared in the two subsets
(Fig. 4a, Additional file 4). To determine whether global
transcriptome analysis could segregate the CLL speci-
mens based on IGVH status, a multi-dimensional scaling
(MDS) plot (Fig. 4b) was constructed based on their
complete transcriptomes. This analysis visualizes the
level of similarity of individual samples within a group.
MDS analysis was able to segregate the five normal B
cells (B1-B5) as they cluster together away from the ten
CLL specimens. The CLL specimens, U-CLL (closed
Table 3 Validation of twenty one differentially expressed genes in CLL. Data from RNA seq analysis (n = 10), qRT-PCR of identical
specimens (n = 10) and qRT-PCR from a test cohort (n = 22) of CLL specimens
CLL downregulated genes Fold downregulation based on
RNA-seq data (n =10)
Fold downregulation RNA-seq
cohort (qRT-PCR data, n = 10)
Fold downregulation in test
cohort qRT-PCR, n = 22)
UACA, uveal autoantigen with coiled-coil domains
and ankyrin repeats
44 9.8 ± 3.9 135 ± 3.7
PTPRK, protein tyrosine and phosphatase, receptor
type, K
24.2 * *
JUP, junction plakoglobin 13.4 44 ± 8.1 32 ± 5
ITGA4, integrin, alpha 4 (CD49D, alpha 4 subunit of
VLA-4 receptor)
10.3 6 ± 2.9 12.9 ± 2.5
BANK1, B-cell scaffold protein with ankyrin repeats 1 7.2 1.23 ± 2 10.1 ± 1.86
RHOB, ras homolog family member B 5.9 6.5 ± 2 1.97 ± 2.1
Jam3, junctional adhesion molecule 3 5.59 3.5 ± 2.5 75.5 ± 3.6
CD69, CD69 molecule 4.7 4.6 ± 1.7 1.07 ± 2.6 (upregulation)
GRASP, (receptor for phosphoinositides 1)-associated
scaffold protein
2.6 36.7 ± 6 9.8 ± 3.8
CLL upregulated genes Fold downregulation based on
RNA-seq data (n =10)
Fold downregulation RNA-seq
cohort (qRT-PCR data, n = 10)
Fold downregulation in test
cohort qRT-PCR, n = 22)
THBS1, thrombospondin 1 528 ± 640 9.8 ± 15.8 12.9 ± 30.8
TGFBR3, transforming growth factor, beta receptor III 373 ± 205 6.6 ± 1.6 30.5 ± 42
GIMAP7, GTPase, IMAP family member 7 340 ± 305 34.2 ± 3.4 9.7 ± 7.7
LYZ, lysozyme 41.8 ± 69 1.5 ± 5.6 10 ± 9.9
PDE4a, phosphodiesterase 4A, cAMP-specific 26.5 ± 33.9 3 ± 3 4 ± 2.3
MYL9, myosin, light chain 9, regulatory 24.9 ± 34 3.5 ± 3.4 8.7 ± 8.9
RAPGEF 3, Rap guanine nucleotide exchange factor
(GEF) 3
24 ± 14.7 17.1 ± 2.9 13.6 ± 11.3
PIM1, pim-1 oncogene 13.9 ± 17 9.4 ± 7.9 6.75 ± 4.6
RXRA, retinoid X receptor, alpha 13.2 ± 12.8 215 ± 196 9.4 ± 9
LCK, lymphocyte specific protein tyrosine kinase 4 ± 2.4 3.2 ± 2.68 4.59 ± 2
CLNK, cytokine-dependent hematopoietic cell linker 3.3 ± 1.8 26 ± 22 36.8 ± 45.2
TGFbeta 1, transforming growth factor, beta 1 1.6 ± 1.1 1.07 ± 2.8 1.4 ± 2.7
*PTPRK expression was not detected in normal B cells therefore fold change could not be calculated
**downregulation of CD69 not validated in test cohort
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boxes) and M-CLL (closed triangles) appear to be separ-
ate from each other but there is overlap of CLL speci-
mens #25, #39, #37. Lack of clear separation of
specimens on this plot indicates that based on the tran-
scriptome data, M- and U-CLL specimens are not fully
distinguishable.
In Additional file 6, the list of differentially expressed
between the two groups (U-CLL and M-CLL) is shown
that was obtained by dividing the mean FPKMs of the
two sub-groups. From this list, we identified three genes
for further analysis on an additional cohort of CLL spec-
imens to determine if the expression of these genes is
different in these two subgroups. The expression of
IGLL5 (immunoglobulin lambda-like polypeptide 5, im-
munoglobulin lambda-like polypeptide) and T (brachy-
ury homolog, embryonic nuclear transcription factor),
was higher in the U-CLL group (top twenty most over-
expressed genes in U-CLL as compared to M-CLL) and
the expression of TFEC (transcription factor EC) was
similarly higher in M-CLL group. The expression of
these genes was determined by qRT-PCR in a separate
cohort of 21 CLL specimens (relative to actin) and is
shown in Fig. 4d, e and f scatter plots. The dotted line
divides the U- and M-CLL specimens and the expression
of these genes in the two sub-groups of CLL specimens
is not significantly different when additional CLL speci-
mens are analyzed. The expression of these three specific
genes and the transcriptome as a whole for the U- and
M-CLL specimens are similar.
RNA splicing alterations in CLL specimens
Besides accurately identifying the expression of the
genes, the RNA–seq data is also useful in characterizing
alternative splicing events. Splicing alterations in CLL
specimens can alter the type of transcripts and thereby
function of a large number of cellular proteins that may
provide the cell with survival advantage. To define the
splicing alterations in CLL specimens, the available
RNA-seq data was analyzed by MATS (Material and
Methods). Fig. 5a is a schematic of the various alterna-
tive splicing (AS) events that were analyzed and the
number of events identified are listed in Fig. 5b. The
analysis identifies AS events both in normal B cells and
CLL specimens. Skipped exon (SE) is the most com-
mon splicing abnormality with 40974 events of which
128 events passing the threshold for significance. The
BA
C D E
Fig. 4 Transcriptomic comparison of IgVH mutated (M-CLL) and non-mutated (U-CLL). a Table with Cuffdiff data showing significant differentially
expressed genes between M- and U-CLL specimens. b MDS plot (Multi-Dimensional Scaling) shows the clustering of the transcriptomic expression
profiles of normal B cells (B1-B5), U-CLL and M-CLL samples (numbered as in Table 1). Axes in the MDS plot (M1 and M2) are arbitrary, and the
values on the axes are distance units. c, d, e qRT-PCR data from the RNA-seq cohort of CLL specimens (n = 10) for three selected genes (T, IGLL5
and TFEC) (relative to actin, log scale). These panels show the scatter-plot qRT-PCR data in a separate cohort of CLL specimens and compare the
expression of the three selected genes in M and U-CLL specimens. The dotted line separates the M- and U-CLL specimens
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complete lists of all the significant splice events in
Fig. 5b table is in Additional file 7. The significant
events in Fig. 5b table are divided into two columns,
B and CLL which indicate whether the splicing event
led to a higher inclusion of the exon in B or CLL
specimens, e.g. 78 SE events resulted in a higher in-
clusion of exon in B cells and in 50 events, the inclu-
sion of the exon was higher in CLL specimens.
As the SE events, were by far the predominant events
they were analyzed by RT-PCR analysis. Sixteen genes
(listed in Additional file 8) were selected for initial ana-
lysis and primers were designed in the neighboring
exons. To confirm DNA amplification of alternatively
spliced exons, RT-PCR analysis was performed on B and
CLL specimen (Additional file 8). Out of sixteen SE
events in two genes there was no PCR amplification and
in three genes only one DNA fragment corresponding to
a single transcript was amplified (gels in Additional file
8). Low level of transcripts that are not amplified by the
PCR is a likely reason that SE events could not be con-
firmed in these three genes. From the remaining eleven
SE events TRIP11, TP53, MBNL2, ARGLU1, PER1, and
PTPRC genes were randomly selected for further ana-
lysis and RT-PCR analysis was performed on B cell (n =
5) and CLL specimens (n = 9, Fig. 6). For each SE event
Fig. 6 describes the exon of the gene that is alternatively
spliced, expected base-pair size of the transcript with
and without skipped exon along with average Inc. level
(inclusion level, based on DNA band densitometry).
TRIP11 (thyroid hormone receptor interactor 11 pro-
tein), tumor suppressor p53 (TP53), ARGLU1 (arginine
and glutamate rich-1), Per1 (period 1) and PTPRC
(CD45) demonstrate at least a two-fold difference in in-
clusion level of the SE exons in their transcripts. The
analysis for MBNL2 (Muscleblind-like splicing regulator
2) did not show any inclusion level difference between
normal B and CLL specimens.
Discussion
Accurate transcriptome analysis is crucial for determin-
ing the expression of genes and thereby activity of sig-
naling pathways that result in growth and survival of
leukemic cells. The data from HTS RNA sequencing is
an improvement over previous methodologies to effect-
ively and efficiently evaluate the entire transcriptome.
The RNA-seq data allows additional analysis of splicing
alterations, transcriptional start sites, identification of
novel signaling pathways and molecular categorization
of specimens that is not feasible with prior genome ana-
lytic techniques. With improvement in HTS-sequencing
technologies and reduction in the cost of sequencing it
is now feasible to compare clinical and biological charac-
teristics of CLL specimens with their global transcrip-
tome profile.
In this study 20 % of genes are identified as differen-
tially expressed (FDR q value < 0.05 and fold change > 2)
in CLL specimens as compared to primary B cells. Re-
cently, Ferreira et al has reported RNA-seq and tran-
scriptome analysis of a large cohort of CLL specimens
[40]. They report 1089 differentially expressed genes
(DEG) between normal B cells and CLL specimens
(FDR < 0.01 and median fold change of more than 3).
This compares well to our analysis of 2091 DEG genes
with a slightly less stringent FDR of < 0.05 and fold
change more than 2. A number of DEG genes identified
by this analysis were also reported by Ferreira et al [40],
e.g. FOS, JUN, CYBRD1, GZMB, FMOD, CTLA-4, etc. In
this study, data from the RNA-seq analysis was addition-
ally also validated by qRT-PCR in a separate cohort of
CLL specimens. Even though a similar expression trend
in expression is observed when the genes from the
RNA-seq analysis are validated by qRT-PCR, in some in-
stances there can be wide variation based on FPKM and
qRT-PCR. There are a number of reasons for the ob-
served differences, e.g. the library preparation for RNA-
A B
Fig. 5 Alternative splicing events in B and CLL specimens. a Schematic showing alternative splicing (AS) events (from MATS analysis website).
b Table with MATS analysis data with different AS events, total events and significant events are shown. B and CLL columns indicate the events
out of all the significant events that had higher inclusion levels in either B or CLL specimens
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seq analysis uses mRNA as starting material while
total RNA was used for qRT-PCR. Another reason is
that the RNA-seq analysis uses the FPKM method for
normalization while actin (reference gene) was used
as a control with qRT-PCR. Even though the Taqman
probes with maximum coverage were used for the
assay, but it is possible that some transcript variants
were not analyzed by qRT-PCR as we observe that
qRT-PCR under-estimates the level of expression as
compared to the RNA-seq data in some genes.
Some of the DEG genes identified in this study have
been reported earlier in microarray studies, e.g. MMP-9
and FMOD (fibromodulin) over-expression in CLL spec-
imens has been described [41, 42]. MMP-9, matrix
metallopeptidase 9, functions by degrading a number of
matrix proteins such as type IV collagen, the major com-
ponent of basement membranes. This gene was found to
be highly expressed by CLL cells present in the bone
marrow and lymph nodes, and contribute to B-CLL pro-
gression by facilitating cell migration and tissue invasion.
FMOD, fibromodulin, is a member of a family of small
interstitial proteoglycans and a component of the extra-
cellular matrix that may also regulate TGF-beta activities
by sequestering TGF-beta into the extracellular matrix
[43]. SiRNA knock-down of this gene results in apop-
tosis of CLL, indicating its role in CLL survival [42].
SEPLG, TYROBP, LEF1 and AMICA1 genes were signifi-
cantly up regulated in a number of CLL specimens.
SELPLG (CD162) is a cell adhesion molecule that is the
counter-receptor for selectins and plays a role in
lymphocyte trafficking. High expression of SELPLG
could potentially aid leukemic cells in trans-endothelial
migration by interacting with the selectins on the endo-
thelium cells [44]. TYROBP or Dap-12 is transmembrane
protein that contains ITAM motifs (immunoreceptor
tyrosine based activation motif ) that are also present in
the B-cell receptor (BCR) signaling components [45].
ITAM motifs are central to BCR signaling as a number
of signaling molecules and adapter proteins assemble at
these motifs. LEF1 (lymphoid enhancer-binding factor-1)
gene encodes a transcription factor that participates in
wnt signaling pathway that is active in CLL specimens.
LEF1 is also involved in the transcriptional activation of
Myc and CyclinD1, and both these genes are also up
regulated in CLL leukemic cells [46]. AMICA1 expres-
sion was marginally higher in the larger cohort of CLL
Fig. 6 Validation of alternative splicing events. RT-PCR analysis of six AS events. For each gene, five B cell specimens and nine CLL specimen was
analyzed. Expected bp (base pair) of the DNA fragments, with schematic of the skipped exon and mean Inc level (inclusion level, based on gel
densitometry) are shown
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specimens (p = 0.032) and is a membrane protein that
interacts with CXADR antigen expressed on epithelial
and endothelial cells [47]. Table 3 lists additional DEG
genes that were confirmed by qRT-PCR analysis. Pim1
kinase over-expression has been reported and this phos-
phorylates CXCR4 receptor that in turn mediates micro-
environment signaling [48]. Similarly PDE4 transcripts
in CLL specimens have been described [49] and Lck is
associated with B-cell receptor signaling and blocking
LCk function results in apoptosis [50].
40–50 % of the DEG genes demonstrate loss of expres-
sion in CLL specimens as compared to B cells. FOS and
JUN down regulation in CLL specimens has been re-
ported but in this study, the expression was not signifi-
cantly lower when this was studied in a larger cohort of
specimens [51–53]. One of the mechanisms of FOS
down regulation is by its interaction with TCL1 onco-
gene that is a potential mechanism of resistance to apop-
tosis observed in CLL cells. DSP (desmoplakin) and
TRIB2 expression were significantly lower in CLL speci-
mens. DSP is a key component of the desmosomes that
form intercellular junctions and loss of its expression is
associated with more invasive behavior of cells [54]. It
can also potentially function as a tumor suppressor gene
by inhibiting the Wnt/β-catenin signaling pathway [55].
TRIB2 is a member of the Tribbles family of proteins
that are similar to serine-threonine kinases but lack cata-
lytic function. These proteins are highly conserved and
modulate a number of signaling pathways [56]. DUSP1,
is a phosphatase that controls cell proliferation and its
expression was not significantly lower in the larger co-
hort of CLL specimens in this analysis [57] as compared
to B cells. Additional genes that are downregulated or si-
lenced in CLL specimens are listed in Table 3. UACA
(Uveal autoantigen with coiled-coil domains and Anky-
rin repeats) that regulates expression of an apoptotic
regulator APAF1 [58]. JUP (junctional plakoglobin or
gamma-catenin) associates with cytoplasmic domains of
cadherins and has tumor and metastasis suppressor ac-
tivity [59]. Based on their reported functions both these
genes are potential tumor suppressor genes in this
leukemia as well.
Based on the MDS (multi-dimensional scaling) ana-
lysis of the RNA-seq data, the normal B cells and CLL
specimens could be segregated on a two-dimensional
plot scaling plot. However, the transcriptome data does
not clearly distinguish the U- and M-CLL transcrip-
tomes as there is overlap on the scaling plot. The two
sub-groups have important biological and clinical differ-
ences [60], but their transcriptomes are not significantly
different. Expression analysis of selected genes (T, IGLL5
and TFEC, ref [61–63]) in the two IGVH sub-groups
gave a similar result with no significant difference of ex-
pression. The study by Ferreira et al [40] reached an
identical conclusion as their analysis could not detect
significant transcriptome differences in these two groups.
This has also been the observation of other groups that
have performed microarray analysis of CLL specimens
and have reached a similar conclusion [13, 14].
Alternative splicing events add another layer of com-
plexity besides genes expression as they can alter the
structure and function of cellular proteins. Skipped
exons are the most common alternative spliced events in
CLL specimens in this study and cancer cells in general
[27, 28]. Splicing abnormalities have increasingly become
more relevant in CLL with the identification of muta-
tions in SF3B1, a splicing factor in a small subset of CLL
patients [9] that confer poorer prognosis and can alter
RNA splicing patterns. In our analysis, we focused on
differentially exon skipping (SE) events as they were by
far the most frequent events as compared to alternative
5’, alternative 3’, mutually exclusive exons, and retained
intron. Confirmation of different inclusion levels in
CD45 (PTPRC, a phosphotyrosine phosphatase), TP53,
ARGLU1, PER1, and Trip11 genes by RT-PCR indicates
that RNA-seq data can be analyzed for splicing alter-
ations. Alternative exon usage in some of these genes
such as PTPRC and p53 is well described in previous
studies [64–68]. PTPRC is a member of the protein tyro-
sine phosphatase family that has a role in antigen recep-
tor signaling, B cell development and may modulate
signaling via integrins and cytokine receptors [66]. A
number of studies have characterized expression of
PTPRC (CD45) isoforms in CLL leukemic cells due to
splicing in exons 4, 5 and 6 that alter the extra-cellular
domain of the protein. It is however, not well under-
stood whether exon skipping and expression of a par-
ticular isoform changes the function of this phosphatase.
Period1 is a gene expressed in a circadian pattern with
probable tumor suppressor function and its alternative
splice forms though reported have not been character-
ized [69]. Alternative exon usage in less well character-
ized genes Trip11 and ARGLU1 was identified by this
RNA-seq analysis and confirmed by RT-PCR. However
their role in CLL biology is currently not clear and this
will require additional studies to sequence novel tran-
scripts in leukemic cells and to determine whether alter-
native exon usage alters the function of the expressed
protein.
Conclusion
The main strength of RNA sequencing data is that be-
sides providing expression analysis it can be further
mined for a number of other genetic abnormalities, in-
cluding splicing alterations, fusion transcripts, alternate
transcription start sites, point mutations, novel tran-
scripts, fusion genes etc. that will provide novel insights
in this leukemia. As there is variability of expression in
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primary leukemic specimens and occasionally between
RNA-seq data and qRT-PCR, further confirmation of
RNA-seq data is required to obtain accurate informa-
tion. Novel DEG and spliced transcripts were identified
that potentially have biological significance in this
leukemia and are valuable leads for discovery of novel
biomarkers and therapeutic targets in this disease.
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